In August 2021 the Australian Digital Health Agency commenced planning on the next National Digital Health Strategy to be launched in 2022. This began with a National Survey and CHF was invited to provide additional input in the form...Read more
About Policy Submissions
We regularly make submissions to national level inquiries. If you are after a submission from earlier than listed here, please contact us.
The Consumers Health Forum has called for an enhanced focus on the central role of consumers in its submission to the Review of the National Medicines Policy.
That is a development in which CHF has played a leading part and we are now urging that this momentum is maintained in the NMP...Read more
The Australian Medical Research and Innovation Strategy (Strategy) is determined by the Australian Medical Research Advisory Board (AMRAB). The Strategy ensures a coherent and consistent approach is adopted in the funding of medical research and innovation from the Medical Research Future
...Read moreThis response advocates that the Australian Commission on Safety and Quality in Health Care (ASQHC) co-design the new Standards with consumers of mental health services. This means not only consulting and engaging with consumers, but offering consumer led development of the Standards.
...Read more
CHF broadly supports the findings and recommendations of the findings and recommendations made in recent and previous years over many years. They confirm that consumers and carers experience a mental health system that fragmented, difficult to understand and navigate, and is not serving mental...Read more
The Primary Health Reform Steering Group was set up to advise the Government on developing the Primary Health Care 10 Year Plan. The Steering Group's discussion paper (...Read more
On 25 February 2021, changes to the Therapeutic Goods (Medical Devices) Regulations 2002 (‘the Regulations’) commenced to introduce a new regulatory framework (the Framework) for medical devices that are designed and manufactured for individual patients (otherwise known as 'personalised' medical...Read more
The Therapeutic Goods Advertising Code (No.2) 2018 (the Code) is the compliance standard that prescribes the minimum requirements for the lawful advertising of therapeutic goods to the public in Australia. It is an important instrument for a range of stakeholders including advertisers,...Read more
CHF submitted this response to the House of Representatives Standing Committee on Health, Aged Care and Sport inquiry into approval processes for new drugs and novel medical technologies in Australia June 2021.
The recommendations, which include feedback from health consumers who are...Read more